Industry
Biotechnology
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Loading...
Open
1.31
Mkt cap
19M
Volume
93K
High
1.38
P/E Ratio
-1.91
52-wk high
3.59
Low
1.27
Div yield
N/A
52-wk low
1.00
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 10:35 am
Portfolio Pulse from Avi Kapoor
June 14, 2024 | 6:13 pm
Portfolio Pulse from Benzinga Insights
June 14, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
June 12, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 10:43 am
Portfolio Pulse from Benzinga Insights
June 10, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
June 05, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
June 04, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 11:03 am
Portfolio Pulse from Benzinga Insights
June 03, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.